Cassava Sciences Inc (SAVA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cassava Sciences reported revenue of $0. Net income was -$91.0M, or -$1.88 per diluted share. Operating activities generated -$32.3M of cash, leaving -$32.9M of free cash flow. At fiscal year end, Cassava Sciences held $118.4M in total assets against $44.0M in total liabilities, including $95.5M of cash and equivalents.
Open the full interactive Cassava Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Cassava Sciences Key Stats
| Share Price | $0.74 |
|---|---|
| Market Cap | $35.7M |
| 52-Week Range | $0.68 – $4.64 |
| Shares Outstanding | 48.3 million (basic, 2025 Q4) |
Cassava Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$6.4M | -$32.9M | -$80.0M | -$106.0M | -$141.4M | -$95.4M |
| Pre-Tax Income | -$6.3M | -$32.4M | -$76.2M | -$97.2M | -$24.3M | -$91.0M |
| Income Tax | — | — | — | — | $0 | $0 |
| Net Income | -$6.3M | -$32.4M | -$76.2M | -$97.2M | -$24.3M | -$91.0M |
| Diluted EPS | -$0.24 | -$0.82 | — | — | -$1.46 | -$1.88 |
Cassava Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$10.8M | -$12.5M | -$10.3M | -$8.6M |
| Diluted EPS | -$0.22 | -$0.26 | — | — |
Cassava Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.5M | $233.4M | $201.0M | $121.1M | $128.6M | $95.5M |
| Current Assets | $94.0M | $244.5M | $211.2M | $129.6M | $136.5M | $97.7M |
| Total Assets | $94.3M | $266.8M | $234.8M | $151.7M | $157.5M | $118.4M |
| Current Liabilities | $1.9M | $12.5M | $7.1M | $14.2M | $11.8M | $43.8M |
| Total Liabilities | $2.1M | $12.9M | $7.3M | $14.2M | $11.8M | $44.0M |
| Shareholders' Equity | $92.2M | $253.9M | $227.5M | $137.5M | $145.7M | $74.4M |
Cassava Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.4M | -$30.2M | -$77.5M | -$82.0M | -$116.9M | -$32.3M |
| Cash From Investing | $360,000 | -$22.2M | -$2.7M | -$414,000 | -$103,000 | -$581,000 |
| Cash From Financing | $75.4M | $192.3M | $47.8M | $2.6M | $124.5M | -$239,000 |
| Free Cash Flow | -$5.4M | -$52.4M | -$80.2M | -$82.4M | -$117.0M | -$32.9M |
Figures from Cassava Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cassava Sciences financials page for every line item.
Cassava Sciences Company Profile
| Ticker | SAVA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Austin, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001069530 |
Frequently Asked Questions
What was Cassava Sciences' revenue in fiscal 2025?
Cassava Sciences (SAVA) reported revenue of $0 for fiscal 2025.
What is Cassava Sciences' annual revenue history?
Cassava Sciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cassava Sciences' net income in fiscal 2025?
Cassava Sciences reported net income of -$91.0M for fiscal 2025.
What was Cassava Sciences' earnings per share (EPS) in fiscal 2025?
Cassava Sciences' diluted EPS was -$1.88 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cassava Sciences generate in fiscal 2025?
Cassava Sciences generated -$32.9M of free cash flow in fiscal 2025.
What was Cassava Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cassava Sciences reported revenue of $0.
How many shares of Cassava Sciences are outstanding?
Cassava Sciences reported a weighted average of 48.3 million basic shares outstanding in 2025 Q4.
What is Cassava Sciences' market cap?
Based on its latest closing price, Cassava Sciences (SAVA) has a market capitalization of about $35.7M.
When does Cassava Sciences' fiscal year end?
Cassava Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is Cassava Sciences headquartered?
Cassava Sciences lists its business address in Austin, Texas in its SEC filings.